Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1412612,elimination half-life,"Preliminary pharmacokinetic data in humans indicate that the plasma drug disappearance curve was biphasic with a mean elimination half-life of 10.6 +/- 1.7 h, total clearance rate of 11.1 +/- 0.4 ml/min/m2, and area under the plasma drug concentration-time curve of 1,289-1,546 ng-h/ml.",Determination of plicamycin in plasma by radioimmunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412612/),h,10.6,1192,DB00437,Allopurinol
,1412612,total clearance rate,"Preliminary pharmacokinetic data in humans indicate that the plasma drug disappearance curve was biphasic with a mean elimination half-life of 10.6 +/- 1.7 h, total clearance rate of 11.1 +/- 0.4 ml/min/m2, and area under the plasma drug concentration-time curve of 1,289-1,546 ng-h/ml.",Determination of plicamycin in plasma by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412612/),[ml] / [m2·min],11.1,1193,DB00437,Allopurinol
,1412612,area under the plasma drug concentration-time curve,"Preliminary pharmacokinetic data in humans indicate that the plasma drug disappearance curve was biphasic with a mean elimination half-life of 10.6 +/- 1.7 h, total clearance rate of 11.1 +/- 0.4 ml/min/m2, and area under the plasma drug concentration-time curve of 1,289-1,546 ng-h/ml.",Determination of plicamycin in plasma by radioimmunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412612/),[ng-h] / [ml],"1,289-1,546",1194,DB00437,Allopurinol
,3581647,renal clearance,"The renal clearance of oxipurinol was reduced from 19.6 +/- 1.5 ml/min during the normal diet to 10.9 +/- 0.8 and 12.0 +/- 0.9 ml/min (both P less than 0.001) during the restricted diet at 2 and 4 weeks, respectively.",Sustained reductions in oxipurinol renal clearance during a restricted diet. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581647/),[ml] / [min],19.6,6219,DB00437,Allopurinol
,3581647,renal clearance,"The renal clearance of oxipurinol was reduced from 19.6 +/- 1.5 ml/min during the normal diet to 10.9 +/- 0.8 and 12.0 +/- 0.9 ml/min (both P less than 0.001) during the restricted diet at 2 and 4 weeks, respectively.",Sustained reductions in oxipurinol renal clearance during a restricted diet. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581647/),[ml] / [min],10.9,6220,DB00437,Allopurinol
,3581647,renal clearance,"The renal clearance of oxipurinol was reduced from 19.6 +/- 1.5 ml/min during the normal diet to 10.9 +/- 0.8 and 12.0 +/- 0.9 ml/min (both P less than 0.001) during the restricted diet at 2 and 4 weeks, respectively.",Sustained reductions in oxipurinol renal clearance during a restricted diet. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581647/),[ml] / [min],12.0,6221,DB00437,Allopurinol
,3581647,half-life,"Furthermore, the plasma oxipurinol half-life was increased from 27.0 +/- 1.7 hours during the normal diet to 51.1 +/- 4.3 and 45.7 +/- 3.7 hours (both P less than 0.001) during the restricted diet at 2 and 4 weeks, respectively.",Sustained reductions in oxipurinol renal clearance during a restricted diet. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581647/),h,27.0,6222,DB00437,Allopurinol
,3581647,half-life,"Furthermore, the plasma oxipurinol half-life was increased from 27.0 +/- 1.7 hours during the normal diet to 51.1 +/- 4.3 and 45.7 +/- 3.7 hours (both P less than 0.001) during the restricted diet at 2 and 4 weeks, respectively.",Sustained reductions in oxipurinol renal clearance during a restricted diet. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581647/),h,51.1,6223,DB00437,Allopurinol
,3581647,half-life,"Furthermore, the plasma oxipurinol half-life was increased from 27.0 +/- 1.7 hours during the normal diet to 51.1 +/- 4.3 and 45.7 +/- 3.7 hours (both P less than 0.001) during the restricted diet at 2 and 4 weeks, respectively.",Sustained reductions in oxipurinol renal clearance during a restricted diet. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3581647/),h,45.7,6224,DB00437,Allopurinol
,31613735,plasma protein binding,"In addition to lesinurad (plasma protein binding 98.2%), the matrix effects from special population plasma on the quantitation of verapamil (PPB 89.6%), allopurinol and oxypurinol (PPB negligible) were also investigated.",The Effects of Special Patient Population Plasma on Pharmacokinetic Quantifications Using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31613735/),%,98.2,10887,DB00437,Allopurinol
,4052144,half-life,The oxipurinol half-life of 17 +/- 5.1 h is prolonged under steady state conditions to 19.7 +/- 5.8 h.,[The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4052144/),h,17,14541,DB00437,Allopurinol
,4052144,half-life,The oxipurinol half-life of 17 +/- 5.1 h is prolonged under steady state conditions to 19.7 +/- 5.8 h.,[The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4052144/),h,19.7,14542,DB00437,Allopurinol
,4052144,half-life,Based on the results of this study and on data from different authors the range of 17-21 h is discussed as the most frequent oxipurinol half-life.,[The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4052144/),h,17-21,14543,DB00437,Allopurinol
,7094977,distribution half-life,"After intravenous injection of allopurinol 300 mg the plasma disappearance was biexponential, with a mean distribution half-life of 2.32 +/- 1.08 min (mean +/- SD) and an elimination half-life of 47.8 +/- 10.6 min.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),min,2.32,20022,DB00437,Allopurinol
,7094977,elimination half-life,"After intravenous injection of allopurinol 300 mg the plasma disappearance was biexponential, with a mean distribution half-life of 2.32 +/- 1.08 min (mean +/- SD) and an elimination half-life of 47.8 +/- 10.6 min.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),min,47.8,20023,DB00437,Allopurinol
,7094977,total clearance,"The total clearance of allopurinol was 11.37 +/- 2.70 ml/min/kg, whereas its renal clearance was only 1.73 +/- 0.79 ml/min/kg.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),[ml] / [kg·min],11.37,20024,DB00437,Allopurinol
,7094977,renal clearance,"The total clearance of allopurinol was 11.37 +/- 2.70 ml/min/kg, whereas its renal clearance was only 1.73 +/- 0.79 ml/min/kg.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),[ml] / [kg·min],1.73,20025,DB00437,Allopurinol
,7094977,half-life,Oxipurinol disappeared monoexponentially from plasma with a mean half-life of 12.2 +/- 2.6 h.,Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),h,12.2,20026,DB00437,Allopurinol
,7094977,renal clearance,Its renal clearance was 0.42 +/- 0.091 ml/min/kg.,Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),[ml] / [kg·min],0.42,20027,DB00437,Allopurinol
,7094977,peak plasma concentration,After oral administration of allopurinol 300 mg the peak plasma concentration of 2.1 +/- 0.6 micrograms/ml (1.5 x 10(-5) M) was reached within 30 to 120 min.,Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),[μg] / [ml],2.1,20028,DB00437,Allopurinol
,7094977,peak level,The peak level of oxipurinol of 5.8 +/- 1.5 micrograms/ml (3.8 x 10(-5) M) was found within 2 to 5 h after intravenous and oral allopurinol.,Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),[μg] / [ml],5.8,20029,DB00437,Allopurinol
,7094977,bioavailability,The bioavailability of oral allopurinol computed from plasma data was 90.4 +/- 8.7%.,Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),%,90.4,20030,DB00437,Allopurinol
,7094977,total recovery from urine,"The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),%,77,20031,DB00437,Allopurinol
,7094977,total recovery from urine,"The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),%,8,20032,DB00437,Allopurinol
,7094977,total recovery from urine,"The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),%,69,20033,DB00437,Allopurinol
,7094977,total recovery from urine,"The total recovery from urine was 77% (allopurinol 8%, oxipurinol 69%) after oral and 88% after i.v. administration.",Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094977/),%,88,20034,DB00437,Allopurinol
,33527723,recoveries,"The recoveries were 99.60 ± 0.67, 99.89 ± 0.98, and 98.71 ± 1.18% for benzbromarone, allopurinol, and oxypurinol, respectively.","Developing, optimizing, and assessing a green electrophoretic method for determination of benzbromarone and allopurinol with its active metabolite in biological and pharmaceutical matrices. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527723/),%,99.60,22885,DB00437,Allopurinol
,33527723,recoveries,"The recoveries were 99.60 ± 0.67, 99.89 ± 0.98, and 98.71 ± 1.18% for benzbromarone, allopurinol, and oxypurinol, respectively.","Developing, optimizing, and assessing a green electrophoretic method for determination of benzbromarone and allopurinol with its active metabolite in biological and pharmaceutical matrices. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527723/),%,99.89,22886,DB00437,Allopurinol
,33527723,recoveries,"The recoveries were 99.60 ± 0.67, 99.89 ± 0.98, and 98.71 ± 1.18% for benzbromarone, allopurinol, and oxypurinol, respectively.","Developing, optimizing, and assessing a green electrophoretic method for determination of benzbromarone and allopurinol with its active metabolite in biological and pharmaceutical matrices. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527723/),%,98.71,22887,DB00437,Allopurinol
,8789699,elimination half-life (t1/2 beta),"The plasma concentration vs. time curves, following intravenous administration of 5 mg/kg, were best described by the biexponential equations Cp = 106.58e(-25.14t) + 159.93e(-10.96t) for allopurinol and Cp = 321.09e(-9.72t) + 82.39e(-0.44t) for oxypurinol, with an elimination half-life (t1/2 beta) of 0.09 h and an area under the curve (AUC) of 19.8 mumol.h/L after intravenous administration, while the t1/2 beta and AUC of oxypurinol were 1.09 h and 231 mumol.h/L, respectively.",The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789699/),h,0.09,25016,DB00437,Allopurinol
,8789699,area under the curve (AUC),"The plasma concentration vs. time curves, following intravenous administration of 5 mg/kg, were best described by the biexponential equations Cp = 106.58e(-25.14t) + 159.93e(-10.96t) for allopurinol and Cp = 321.09e(-9.72t) + 82.39e(-0.44t) for oxypurinol, with an elimination half-life (t1/2 beta) of 0.09 h and an area under the curve (AUC) of 19.8 mumol.h/L after intravenous administration, while the t1/2 beta and AUC of oxypurinol were 1.09 h and 231 mumol.h/L, respectively.",The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789699/),[h·μM] / [l],19.8,25017,DB00437,Allopurinol
,8789699,t1/2 beta,"The plasma concentration vs. time curves, following intravenous administration of 5 mg/kg, were best described by the biexponential equations Cp = 106.58e(-25.14t) + 159.93e(-10.96t) for allopurinol and Cp = 321.09e(-9.72t) + 82.39e(-0.44t) for oxypurinol, with an elimination half-life (t1/2 beta) of 0.09 h and an area under the curve (AUC) of 19.8 mumol.h/L after intravenous administration, while the t1/2 beta and AUC of oxypurinol were 1.09 h and 231 mumol.h/L, respectively.",The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789699/),h,1.09,25018,DB00437,Allopurinol
,8789699,AUC,"The plasma concentration vs. time curves, following intravenous administration of 5 mg/kg, were best described by the biexponential equations Cp = 106.58e(-25.14t) + 159.93e(-10.96t) for allopurinol and Cp = 321.09e(-9.72t) + 82.39e(-0.44t) for oxypurinol, with an elimination half-life (t1/2 beta) of 0.09 h and an area under the curve (AUC) of 19.8 mumol.h/L after intravenous administration, while the t1/2 beta and AUC of oxypurinol were 1.09 h and 231 mumol.h/L, respectively.",The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789699/),[h·μM] / [l],231,25019,DB00437,Allopurinol
,8789699,bioavailability,"The bioavailability of allopurinol was low (14.3%), although no allopurinol was detected in the plasma of two horses after oral administration of allopurinol was equivalent to that of intravenously injected oxypurinol.",The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8789699/),%,14.3,25020,DB00437,Allopurinol
,3719584,steady-state plasma level,The steady-state plasma level increased from 3.37 to 7.49 microM with dose increases from 1.25 to 2.25 g/m2/day.,Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719584/),μM,3.37 to 7.49,28024,DB00437,Allopurinol
,3719584,Clearance,Clearance ranged from 1.79 to 2.41 L/min/m2.,Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3719584/),[l] / [m2·min],1.79 to 2.41,28025,DB00437,Allopurinol
,3292102,body clearance,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [h·kg],0.7,28702,DB00437,Allopurinol
,3292102,steady-state volume of distribution,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [kg],0.8,28703,DB00437,Allopurinol
,3292102,elimination half-life,The elimination half-life of unchanged captopril was approximately 2 hours.,Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),h,2,28704,DB00437,Allopurinol
,3292102,bioavailability,"In healthy subjects, about 70 to 75% of an oral dose is absorbed and the bioavailability of captopril is approximately 65%.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),%,65,28705,DB00437,Allopurinol
,7194674,Detection limits,Detection limits for this method of assay are 0.1 microgram benzbromarone/ml serum.,[Determination of benzbromarone in serum following combined therapy with allopurinol and benzbromarone (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194674/),,0,34319,DB00437,Allopurinol
,7194674,half-life,The half-life of benzbromarone is 2.6 h.,[Determination of benzbromarone in serum following combined therapy with allopurinol and benzbromarone (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194674/),h,2.6,34320,DB00437,Allopurinol
,23475133,clearance,"The population estimates for allopurinol clearance, inter-compartmental clearance, central and peripheral volume were 50, 142 L/h/70 kg FFM, 11.4, 91 L/70 kg FFM, respectively, with a between-subject variability of 33 % (coefficient of variance, CV) for allopurinol clearance.",The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23475133/),[l] / [70·h·kg],"50, 142",34956,DB00437,Allopurinol
,23475133,clearance,"Oxypurinol clearance and volume of distribution were estimated to be 0.78 L/h per 6 L/h creatinine clearance/70 kg FFM and 41 L/70 kg FFM in the final model, with a between-subject variability of 28 and 15 % (CV), respectively.",The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23475133/),[l] / [·h],0.78,34957,DB00437,Allopurinol
,6580097,peak plasma concentration,"Studies conducted initially in rhesus monkeys and subsequently in man with 6-MP doses of 100 mg/m2 and 75 mg/m2, demonstrated that allopurinol pretreatment resulted in a nearly 400% increase in peak plasma concentration of oral 6-MP in monkeys (from a mean of 0.54 microM to a mean of 2.1 microM) and a 500% increase in man (0.74 microM to 3.7 microM).",Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),μM,0.54,40620,DB00437,Allopurinol
,6580097,peak plasma concentration,"Studies conducted initially in rhesus monkeys and subsequently in man with 6-MP doses of 100 mg/m2 and 75 mg/m2, demonstrated that allopurinol pretreatment resulted in a nearly 400% increase in peak plasma concentration of oral 6-MP in monkeys (from a mean of 0.54 microM to a mean of 2.1 microM) and a 500% increase in man (0.74 microM to 3.7 microM).",Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),μM,2.1,40621,DB00437,Allopurinol
,6580097,peak plasma concentration,"Studies conducted initially in rhesus monkeys and subsequently in man with 6-MP doses of 100 mg/m2 and 75 mg/m2, demonstrated that allopurinol pretreatment resulted in a nearly 400% increase in peak plasma concentration of oral 6-MP in monkeys (from a mean of 0.54 microM to a mean of 2.1 microM) and a 500% increase in man (0.74 microM to 3.7 microM).",Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),μM,0.74,40622,DB00437,Allopurinol
,6580097,peak plasma concentration,"Studies conducted initially in rhesus monkeys and subsequently in man with 6-MP doses of 100 mg/m2 and 75 mg/m2, demonstrated that allopurinol pretreatment resulted in a nearly 400% increase in peak plasma concentration of oral 6-MP in monkeys (from a mean of 0.54 microM to a mean of 2.1 microM) and a 500% increase in man (0.74 microM to 3.7 microM).",Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),μM,3.7,40623,DB00437,Allopurinol
,6580097,plasma AUC,Allopurinol pretreatment also led to a 300% increase in plasma AUC in monkeys after oral 6-MP (from a mean of 121 microM/min to a mean of 391 microM/min) and a 500% increase in AUC in man (from a mean of 142 microM/min to a mean of 716 microM/min).,Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),[μM] / [min],121,40624,DB00437,Allopurinol
,6580097,plasma AUC,Allopurinol pretreatment also led to a 300% increase in plasma AUC in monkeys after oral 6-MP (from a mean of 121 microM/min to a mean of 391 microM/min) and a 500% increase in AUC in man (from a mean of 142 microM/min to a mean of 716 microM/min).,Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),[μM] / [min],391,40625,DB00437,Allopurinol
,6580097,AUC,Allopurinol pretreatment also led to a 300% increase in plasma AUC in monkeys after oral 6-MP (from a mean of 121 microM/min to a mean of 391 microM/min) and a 500% increase in AUC in man (from a mean of 142 microM/min to a mean of 716 microM/min).,Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),[μM] / [min],142,40626,DB00437,Allopurinol
,6580097,AUC,Allopurinol pretreatment also led to a 300% increase in plasma AUC in monkeys after oral 6-MP (from a mean of 121 microM/min to a mean of 391 microM/min) and a 500% increase in AUC in man (from a mean of 142 microM/min to a mean of 716 microM/min).,Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6580097/),[μM] / [min],716,40627,DB00437,Allopurinol
,2029827,elimination half-life,"Allopurinol riboside peaks in plasma 1.6 hours after administration, has an elimination half-life of 3 hours, and steady-state concentrations in the therapeutic range.",Pharmacokinetics and metabolism of allopurinol riboside. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029827/),h,3,40869,DB00437,Allopurinol
,22300439,CL/F(m),"CL/F(m) for patients with normal, mild, moderate and severe renal impairment was 1.8, 0.6, 0.3 and 0.18 l h(-1), respectively.",The pharmacokinetics of oxypurinol in people with gout. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300439/),[l] / [h],1.8,66819,DB00437,Allopurinol
,22300439,CL/F(m),"CL/F(m) for patients with normal, mild, moderate and severe renal impairment was 1.8, 0.6, 0.3 and 0.18 l h(-1), respectively.",The pharmacokinetics of oxypurinol in people with gout. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300439/),[l] / [h],0.6,66820,DB00437,Allopurinol
,22300439,CL/F(m),"CL/F(m) for patients with normal, mild, moderate and severe renal impairment was 1.8, 0.6, 0.3 and 0.18 l h(-1), respectively.",The pharmacokinetics of oxypurinol in people with gout. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300439/),[l] / [h],0.3,66821,DB00437,Allopurinol
,22300439,CL/F(m),"CL/F(m) for patients with normal, mild, moderate and severe renal impairment was 1.8, 0.6, 0.3 and 0.18 l h(-1), respectively.",The pharmacokinetics of oxypurinol in people with gout. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22300439/),[l] / [h],0.18,66822,DB00437,Allopurinol
,29531784,Emax,"Combination treatment decreased sUA in dose-dependent manner: least-squares means Emax was 47%, 59%, 60%, 67%, 68% and 74% for verinurad doses 2.5, 5, 7.5, 10, 15 and 20 mg plus allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, 600 mg once daily and 300 mg twice daily.","Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29531784/),%,47,66928,DB00437,Allopurinol
,29531784,Emax,"Combination treatment decreased sUA in dose-dependent manner: least-squares means Emax was 47%, 59%, 60%, 67%, 68% and 74% for verinurad doses 2.5, 5, 7.5, 10, 15 and 20 mg plus allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, 600 mg once daily and 300 mg twice daily.","Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29531784/),%,59,66929,DB00437,Allopurinol
,29531784,Emax,"Combination treatment decreased sUA in dose-dependent manner: least-squares means Emax was 47%, 59%, 60%, 67%, 68% and 74% for verinurad doses 2.5, 5, 7.5, 10, 15 and 20 mg plus allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, 600 mg once daily and 300 mg twice daily.","Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29531784/),%,60,66930,DB00437,Allopurinol
,29531784,Emax,"Combination treatment decreased sUA in dose-dependent manner: least-squares means Emax was 47%, 59%, 60%, 67%, 68% and 74% for verinurad doses 2.5, 5, 7.5, 10, 15 and 20 mg plus allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, 600 mg once daily and 300 mg twice daily.","Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29531784/),%,67,66931,DB00437,Allopurinol
,29531784,Emax,"Combination treatment decreased sUA in dose-dependent manner: least-squares means Emax was 47%, 59%, 60%, 67%, 68% and 74% for verinurad doses 2.5, 5, 7.5, 10, 15 and 20 mg plus allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, 600 mg once daily and 300 mg twice daily.","Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29531784/),%,68,66932,DB00437,Allopurinol
,29531784,Emax,"Combination treatment decreased sUA in dose-dependent manner: least-squares means Emax was 47%, 59%, 60%, 67%, 68% and 74% for verinurad doses 2.5, 5, 7.5, 10, 15 and 20 mg plus allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, 600 mg once daily and 300 mg twice daily.","Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29531784/),%,74,66933,DB00437,Allopurinol
,29531784,Emax,"Combination treatment decreased sUA in dose-dependent manner: least-squares means Emax was 47%, 59%, 60%, 67%, 68% and 74% for verinurad doses 2.5, 5, 7.5, 10, 15 and 20 mg plus allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, 600 mg once daily and 300 mg twice daily.","Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29531784/),%,40,66934,DB00437,Allopurinol
,29531784,Emax,"Combination treatment decreased sUA in dose-dependent manner: least-squares means Emax was 47%, 59%, 60%, 67%, 68% and 74% for verinurad doses 2.5, 5, 7.5, 10, 15 and 20 mg plus allopurinol 300 mg once daily, versus 40%, 54% and 54% for allopurinol 300 mg once daily, 600 mg once daily and 300 mg twice daily.","Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29531784/),%,54,66935,DB00437,Allopurinol
,3752167,renal o,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),[ml] / [min],21.1,67171,DB00437,Allopurinol
,3752167,renal o,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),[ml] / [min],20.4,67172,DB00437,Allopurinol
,3752167,clearance,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),[ml] / [min],21.1,67173,DB00437,Allopurinol
,3752167,clearance,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),[ml] / [min],20.4,67174,DB00437,Allopurinol
,3752167,half-life,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),h,23.7,67175,DB00437,Allopurinol
,3752167,half-life,No change in renal oxipurinol clearance (21.1 +/- 5.9 vs. 20.4 +/- 8.7 ml/min) or serum oxipurinol half-life (23.7 +/- 4.2 vs. 23.4 +/- 4.4 hours) was noted with the addition of thiazides.,Evaluation of a thiazide-allopurinol drug interaction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752167/),h,23.4,67176,DB00437,Allopurinol
,27683090,AUC7days,"Allopurinol 100 mg daily produced an AUC7days of 279 μmol/L h in dialysis patients, a value 50-75 % lower than the AUC7days predicted for patients with normal renal function taking 200 to 400 mg daily (427-855 μmol/L h).",A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27683090/),[μM] / [h·l],279,69278,DB00437,Allopurinol
,27683090,AUC7days,"Allopurinol 100 mg daily produced an AUC7days of 279 μmol/L h in dialysis patients, a value 50-75 % lower than the AUC7days predicted for patients with normal renal function taking 200 to 400 mg daily (427-855 μmol/L h).",A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27683090/),[μM] / [h·l],427-855,69279,DB00437,Allopurinol
,27683090,total,"The population dialytic and total (non-dialytic) clearance of oxypurinol were found to be 8.23 and 1.23 L/h, standardised to a fat-free mass of 70 kg and creatinine clearance of 6 L/h, respectively.",A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27683090/),[l] / [h],8.23,69280,DB00437,Allopurinol
,27683090,total,"The population dialytic and total (non-dialytic) clearance of oxypurinol were found to be 8.23 and 1.23 L/h, standardised to a fat-free mass of 70 kg and creatinine clearance of 6 L/h, respectively.",A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27683090/),[l] / [h],1.23,69281,DB00437,Allopurinol
,27683090,clearance,"The population dialytic and total (non-dialytic) clearance of oxypurinol were found to be 8.23 and 1.23 L/h, standardised to a fat-free mass of 70 kg and creatinine clearance of 6 L/h, respectively.",A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27683090/),[l] / [h],1.23,69282,DB00437,Allopurinol
,7438330,terminal plasma t1/2,"In four dogs, after IV administration of AT-5-14C at 10 mg/kg (200 mg/m2), 150-200 muCi per animal, the terminal plasma t1/2 of AT was 13 h, and less than 10% of the administered dose appeared in the urine in 5 h.","The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438330/),h,13,69328,DB00437,Allopurinol
,7438330,plasma t1/2,"When the dose was raised to 25 mg/kg (500 mg/m2) in four dogs, the average plasma t1/2 of AT was 10 h; the 5-h cumulative excretion of the agent was 9% of the dose in the urine, 0.3% in the bile, and 0.1% as 14CO2 in the expired air.","The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438330/),h,10,69329,DB00437,Allopurinol
,7438330,cumulative excretion,"When the dose was raised to 25 mg/kg (500 mg/m2) in four dogs, the average plasma t1/2 of AT was 10 h; the 5-h cumulative excretion of the agent was 9% of the dose in the urine, 0.3% in the bile, and 0.1% as 14CO2 in the expired air.","The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438330/),%,9,69330,DB00437,Allopurinol
,7438330,cumulative excretion,"When the dose was raised to 25 mg/kg (500 mg/m2) in four dogs, the average plasma t1/2 of AT was 10 h; the 5-h cumulative excretion of the agent was 9% of the dose in the urine, 0.3% in the bile, and 0.1% as 14CO2 in the expired air.","The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438330/),%,0.3,69331,DB00437,Allopurinol
,7438330,cumulative excretion,"When the dose was raised to 25 mg/kg (500 mg/m2) in four dogs, the average plasma t1/2 of AT was 10 h; the 5-h cumulative excretion of the agent was 9% of the dose in the urine, 0.3% in the bile, and 0.1% as 14CO2 in the expired air.","The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438330/),%,0.1,69332,DB00437,Allopurinol
,7438330,total clearance,The average total clearance of AT was 0.70 ml/kg/min.,"The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438330/),[ml] / [kg·min],0.70,69333,DB00437,Allopurinol
,8461629,milk/plasma ratio,The milk/plasma ratio in the mother 2 h (4 h) after drug ingestion was 0.9 (1.4) for allopurinol and 3.9 (2.4) for oxypurinol.,Allopurinol and oxypurinol in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461629/),,0.9,76074,DB00437,Allopurinol
,8461629,milk/plasma ratio,The milk/plasma ratio in the mother 2 h (4 h) after drug ingestion was 0.9 (1.4) for allopurinol and 3.9 (2.4) for oxypurinol.,Allopurinol and oxypurinol in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8461629/),,3.9,76075,DB00437,Allopurinol
,7596124,Half-life (t1/2),"Half-life (t1/2) of drug penetration into the heart was dose independent (1.8 min), whereas for the 10-mg/kg dose terminal elimination t1/2 (96 min) was much prolonged and ISF clearance (9.6 l/min kg) was reduced as compared with that induced by 1 mg/kg (28 min and 30.4 l/min kg) probably due to capacity limitation of allopurinol conversion to oxypurinol by Xa dehydrogenase/oxydase (Xa D/O).","Allopurinol: kinetics, inhibition of xanthine oxidase activity, and protective effect in ischemic-reperfused canine heart as studied by cardiac microdialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596124/),min,1.8,76990,DB00437,Allopurinol
,7596124,terminal elimination t1/2,"Half-life (t1/2) of drug penetration into the heart was dose independent (1.8 min), whereas for the 10-mg/kg dose terminal elimination t1/2 (96 min) was much prolonged and ISF clearance (9.6 l/min kg) was reduced as compared with that induced by 1 mg/kg (28 min and 30.4 l/min kg) probably due to capacity limitation of allopurinol conversion to oxypurinol by Xa dehydrogenase/oxydase (Xa D/O).","Allopurinol: kinetics, inhibition of xanthine oxidase activity, and protective effect in ischemic-reperfused canine heart as studied by cardiac microdialysis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596124/),min,96,76991,DB00437,Allopurinol
,7596124,clearance,"Half-life (t1/2) of drug penetration into the heart was dose independent (1.8 min), whereas for the 10-mg/kg dose terminal elimination t1/2 (96 min) was much prolonged and ISF clearance (9.6 l/min kg) was reduced as compared with that induced by 1 mg/kg (28 min and 30.4 l/min kg) probably due to capacity limitation of allopurinol conversion to oxypurinol by Xa dehydrogenase/oxydase (Xa D/O).","Allopurinol: kinetics, inhibition of xanthine oxidase activity, and protective effect in ischemic-reperfused canine heart as studied by cardiac microdialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596124/),[l] / [kg·min],9.6,76992,DB00437,Allopurinol
,7596124,clearance,"Half-life (t1/2) of drug penetration into the heart was dose independent (1.8 min), whereas for the 10-mg/kg dose terminal elimination t1/2 (96 min) was much prolonged and ISF clearance (9.6 l/min kg) was reduced as compared with that induced by 1 mg/kg (28 min and 30.4 l/min kg) probably due to capacity limitation of allopurinol conversion to oxypurinol by Xa dehydrogenase/oxydase (Xa D/O).","Allopurinol: kinetics, inhibition of xanthine oxidase activity, and protective effect in ischemic-reperfused canine heart as studied by cardiac microdialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596124/),min,28,76993,DB00437,Allopurinol
,7596124,clearance,"Half-life (t1/2) of drug penetration into the heart was dose independent (1.8 min), whereas for the 10-mg/kg dose terminal elimination t1/2 (96 min) was much prolonged and ISF clearance (9.6 l/min kg) was reduced as compared with that induced by 1 mg/kg (28 min and 30.4 l/min kg) probably due to capacity limitation of allopurinol conversion to oxypurinol by Xa dehydrogenase/oxydase (Xa D/O).","Allopurinol: kinetics, inhibition of xanthine oxidase activity, and protective effect in ischemic-reperfused canine heart as studied by cardiac microdialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7596124/),[l] / [kg·min],30.4,76994,DB00437,Allopurinol
,3391630,half-life,"Samples obtained over 84 h showed prolonged elimination of allopurinol, with a half-life of 3.6 h, and oxipurinol, with a half-life of 26 h.",Allopurinol kinetics after massive overdosage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391630/),h,3.6,82563,DB00437,Allopurinol
,3391630,half-life,"Samples obtained over 84 h showed prolonged elimination of allopurinol, with a half-life of 3.6 h, and oxipurinol, with a half-life of 26 h.",Allopurinol kinetics after massive overdosage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391630/),h,26,82564,DB00437,Allopurinol
,21285173,renal urate clearance,"Addition of probenecid 500 mg/day to allopurinol therapy decreased plasma urate concentrations by 25%, from mean 0.37 mmol/l (95% CI 0.33-0.41) to mean 0.28 mmol/l (95% CI 0.24-0.32) (p < 0.001); and increased renal urate clearance by 62%, from mean 6.0 ml/min (95% CI 4.5-7.5) to mean 9.6 ml/min (95% CI 6.9-12.3) (p < 0.001).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[ml] / [min],6.0,86741,DB00437,Allopurinol
,21285173,renal urate clearance,"Addition of probenecid 500 mg/day to allopurinol therapy decreased plasma urate concentrations by 25%, from mean 0.37 mmol/l (95% CI 0.33-0.41) to mean 0.28 mmol/l (95% CI 0.24-0.32) (p < 0.001); and increased renal urate clearance by 62%, from mean 6.0 ml/min (95% CI 4.5-7.5) to mean 9.6 ml/min (95% CI 6.9-12.3) (p < 0.001).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[ml] / [min],9.6,86742,DB00437,Allopurinol
,21285173,steady-state plasma oxypurinol concentrations,"Average steady-state plasma oxypurinol concentrations decreased by 26%, from mean 11.1 mg/l (95% CI 5.0-17.3) to mean 8.2 mg/l (95% CI 4.0-12.4) (p < 0.001); and renal oxypurinol clearance increased by 24%, from mean 12.7 ml/min (95% CI 9.6-15.8) to mean 16.1 ml/min (95% CI 12.0-20.2) (p < 0.05).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[mg] / [l],11.1,86743,DB00437,Allopurinol
,21285173,steady-state plasma oxypurinol concentrations,"Average steady-state plasma oxypurinol concentrations decreased by 26%, from mean 11.1 mg/l (95% CI 5.0-17.3) to mean 8.2 mg/l (95% CI 4.0-12.4) (p < 0.001); and renal oxypurinol clearance increased by 24%, from mean 12.7 ml/min (95% CI 9.6-15.8) to mean 16.1 ml/min (95% CI 12.0-20.2) (p < 0.05).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[mg] / [l],8.2,86744,DB00437,Allopurinol
,21285173,renal oxypurinol clearance,"Average steady-state plasma oxypurinol concentrations decreased by 26%, from mean 11.1 mg/l (95% CI 5.0-17.3) to mean 8.2 mg/l (95% CI 4.0-12.4) (p < 0.001); and renal oxypurinol clearance increased by 24%, from mean 12.7 ml/min (95% CI 9.6-15.8) to mean 16.1 ml/min (95% CI 12.0-20.2) (p < 0.05).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[ml] / [min],12.7,86745,DB00437,Allopurinol
,21285173,renal oxypurinol clearance,"Average steady-state plasma oxypurinol concentrations decreased by 26%, from mean 11.1 mg/l (95% CI 5.0-17.3) to mean 8.2 mg/l (95% CI 4.0-12.4) (p < 0.001); and renal oxypurinol clearance increased by 24%, from mean 12.7 ml/min (95% CI 9.6-15.8) to mean 16.1 ml/min (95% CI 12.0-20.2) (p < 0.05).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21285173/),[ml] / [min],16.1,86746,DB00437,Allopurinol
over,1257607,peak plasma concentration,"Theophylline peak plasma concentration of over 170 ng/ml average was observed when 300 mg of caffeine, equivalent to 2-3 cups of coffee, was administered to humans.",The human metabolism of caffeine to theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1257607/),[ng] / [ml],170,97595,DB00437,Allopurinol
,32453913,half-maximal inhibitory concentration,"In vitro, febuxostat inhibited the ATP-dependent uptake of rosuvastatin into BCRP-overexpressing membrane vesicles with a half-maximal inhibitory concentration of 0.35 µM, whereas allopurinol showed no inhibition with concentrations up to 200 µM.","Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453913/),μM,0.35,102626,DB00437,Allopurinol
,10583019,Total clearance,"Total clearance of allopurinol was not different in elderly (15.7+/-3.8 ml min-1 kg-1, mean+/-s.e. mean) and young subjects (15.7+/-2.1), whereas total clearance of oxipurinol was significantly reduced in the aged (0.24+/-0.03) compared with young controls (0.37+/-0.05) as was the distribution volume of oxipurinol (0.60+/-0.09 and 0.84+/-0.07 l kg-1, respectively).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),[ml] / [kg·min],15.7,105672,DB00437,Allopurinol
,10583019,Total clearance,"Total clearance of allopurinol was not different in elderly (15.7+/-3.8 ml min-1 kg-1, mean+/-s.e. mean) and young subjects (15.7+/-2.1), whereas total clearance of oxipurinol was significantly reduced in the aged (0.24+/-0.03) compared with young controls (0.37+/-0.05) as was the distribution volume of oxipurinol (0.60+/-0.09 and 0.84+/-0.07 l kg-1, respectively).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),[ml] / [kg·min],15.7,105673,DB00437,Allopurinol
,10583019,total clearance,"Total clearance of allopurinol was not different in elderly (15.7+/-3.8 ml min-1 kg-1, mean+/-s.e. mean) and young subjects (15.7+/-2.1), whereas total clearance of oxipurinol was significantly reduced in the aged (0.24+/-0.03) compared with young controls (0.37+/-0.05) as was the distribution volume of oxipurinol (0.60+/-0.09 and 0.84+/-0.07 l kg-1, respectively).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),,0.24,105674,DB00437,Allopurinol
,10583019,total clearance,"Total clearance of allopurinol was not different in elderly (15.7+/-3.8 ml min-1 kg-1, mean+/-s.e. mean) and young subjects (15.7+/-2.1), whereas total clearance of oxipurinol was significantly reduced in the aged (0.24+/-0.03) compared with young controls (0.37+/-0.05) as was the distribution volume of oxipurinol (0.60+/-0.09 and 0.84+/-0.07 l kg-1, respectively).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),,0.37,105675,DB00437,Allopurinol
,10583019,distribution volume,"Total clearance of allopurinol was not different in elderly (15.7+/-3.8 ml min-1 kg-1, mean+/-s.e. mean) and young subjects (15.7+/-2.1), whereas total clearance of oxipurinol was significantly reduced in the aged (0.24+/-0.03) compared with young controls (0.37+/-0.05) as was the distribution volume of oxipurinol (0.60+/-0.09 and 0.84+/-0.07 l kg-1, respectively).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),[l] / [kg],0.60,105676,DB00437,Allopurinol
,10583019,distribution volume,"Total clearance of allopurinol was not different in elderly (15.7+/-3.8 ml min-1 kg-1, mean+/-s.e. mean) and young subjects (15.7+/-2.1), whereas total clearance of oxipurinol was significantly reduced in the aged (0.24+/-0.03) compared with young controls (0.37+/-0.05) as was the distribution volume of oxipurinol (0.60+/-0.09 and 0.84+/-0.07 l kg-1, respectively).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),[l] / [kg],0.84,105677,DB00437,Allopurinol
,10583019,Fractional peroral bioavailability,"Fractional peroral bioavailability of allopurinol was 0.81+/-0.16 (n=4, two elderly and two young subjects).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),,0.81,105678,DB00437,Allopurinol
,10583019,maximal plasma concentrations,"Although maximal plasma concentrations of oxipurinol were significantly higher in elderly (5. 63+/-0.83 microgram ml-1 ) than in young persons (3.75+/-0.25) as was the area under the oxipurinol plasma concentration-time curve, AUC (260+/-46 and 166+/-23 microgram ml-1 h, respectively), the pharmacodynamic effect of oxipurinol was smaller in elderly than young subjects (time-dependent decrease of plasma uric acid 83+/-30 microgram ml-1 h in elderly compared with 176+/-21 in young controls).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),[μg] / [ml],5. 63,105679,DB00437,Allopurinol
,10583019,maximal plasma concentrations,"Although maximal plasma concentrations of oxipurinol were significantly higher in elderly (5. 63+/-0.83 microgram ml-1 ) than in young persons (3.75+/-0.25) as was the area under the oxipurinol plasma concentration-time curve, AUC (260+/-46 and 166+/-23 microgram ml-1 h, respectively), the pharmacodynamic effect of oxipurinol was smaller in elderly than young subjects (time-dependent decrease of plasma uric acid 83+/-30 microgram ml-1 h in elderly compared with 176+/-21 in young controls).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),,3.75,105680,DB00437,Allopurinol
,10583019,"area under the oxipurinol plasma concentration-time curve, AUC","Although maximal plasma concentrations of oxipurinol were significantly higher in elderly (5. 63+/-0.83 microgram ml-1 ) than in young persons (3.75+/-0.25) as was the area under the oxipurinol plasma concentration-time curve, AUC (260+/-46 and 166+/-23 microgram ml-1 h, respectively), the pharmacodynamic effect of oxipurinol was smaller in elderly than young subjects (time-dependent decrease of plasma uric acid 83+/-30 microgram ml-1 h in elderly compared with 176+/-21 in young controls).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),[h·μg] / [ml],260,105681,DB00437,Allopurinol
,10583019,"area under the oxipurinol plasma concentration-time curve, AUC","Although maximal plasma concentrations of oxipurinol were significantly higher in elderly (5. 63+/-0.83 microgram ml-1 ) than in young persons (3.75+/-0.25) as was the area under the oxipurinol plasma concentration-time curve, AUC (260+/-46 and 166+/-23 microgram ml-1 h, respectively), the pharmacodynamic effect of oxipurinol was smaller in elderly than young subjects (time-dependent decrease of plasma uric acid 83+/-30 microgram ml-1 h in elderly compared with 176+/-21 in young controls).",Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583019/),[h·μg] / [ml],166,105682,DB00437,Allopurinol
,33611729,clearance,"Our final model predicted a mannitol clearance of 0.15 L/h for a typical asphyxia neonate (39.5 weeks, birthweight 3.25 kg, no TH), lower than the reported value of 0.33 L/h for a healthy neonate of similar age and weight.","Glomerular Filtration Rate in Asphyxiated Neonates Under Therapeutic Whole-Body Hypothermia, Quantified by Mannitol Clearance. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33611729/),[l] / [h],0.15,112054,DB00437,Allopurinol
,33611729,clearance,"Our final model predicted a mannitol clearance of 0.15 L/h for a typical asphyxia neonate (39.5 weeks, birthweight 3.25 kg, no TH), lower than the reported value of 0.33 L/h for a healthy neonate of similar age and weight.","Glomerular Filtration Rate in Asphyxiated Neonates Under Therapeutic Whole-Body Hypothermia, Quantified by Mannitol Clearance. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33611729/),[l] / [h],0.33,112055,DB00437,Allopurinol
,3940216,peak blood concentrations,"With IV administration a dose of 50 mg/kg gave peak blood concentrations of 100 micrograms/ml in mice, while 25 mg/kg gave peak plasma concentrations of 27 micrograms/ml in dogs.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),[μg] / [ml],100,115688,DB00437,Allopurinol
,3940216,peak plasma concentrations,"With IV administration a dose of 50 mg/kg gave peak blood concentrations of 100 micrograms/ml in mice, while 25 mg/kg gave peak plasma concentrations of 27 micrograms/ml in dogs.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),[μg] / [ml],27,115689,DB00437,Allopurinol
,3940216,bioavailabilities,"Peak concentrations were 3 to 5-fold lower for the IP route in mice and the oral route in dogs, and the bioavailabilities were 85% and 40%, respectively.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),%,85,115690,DB00437,Allopurinol
,3940216,bioavailabilities,"Peak concentrations were 3 to 5-fold lower for the IP route in mice and the oral route in dogs, and the bioavailabilities were 85% and 40%, respectively.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),%,40,115691,DB00437,Allopurinol
,3940216,Elimination t1/2,Elimination t1/2 values were 1.4-2 h in mice and 2.5-4 h in dogs and were independent of route of administration.,CB 1954 revisited. I. Disposition kinetics and metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),h,1.4-2,115692,DB00437,Allopurinol
,3940216,Elimination t1/2,Elimination t1/2 values were 1.4-2 h in mice and 2.5-4 h in dogs and were independent of route of administration.,CB 1954 revisited. I. Disposition kinetics and metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),h,2.5-4,115693,DB00437,Allopurinol
,3940216,Plasma protein binding,Plasma protein binding was 57% but tissue penetration in mice was generally good.,CB 1954 revisited. I. Disposition kinetics and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),%,57,115694,DB00437,Allopurinol
,3940216,Tu,"Tumour: plasma ratios were 50%-90%, while brain: plasma ratios were lower, at 37%-50%.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),,50,115695,DB00437,Allopurinol
,3940216,total recovery,"The parent drug and several metabolites were identified and quantified in mouse urine, the total recovery being 24%-29%, of which 16%-25% was parent drug.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),%,24,115696,DB00437,Allopurinol
,3940216,total recovery,"The parent drug and several metabolites were identified and quantified in mouse urine, the total recovery being 24%-29%, of which 16%-25% was parent drug.",CB 1954 revisited. I. Disposition kinetics and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940216/),%,16,115697,DB00437,Allopurinol
,33931953,half-life,Subjects homozygous for p.Q141K had a longer half-life (34.2 ± 12.2 h vs. 19.1 ± 1.42 h) of oxypurinol.,Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33931953/),h,34.2,125512,DB00437,Allopurinol
,33931953,half-life,Subjects homozygous for p.Q141K had a longer half-life (34.2 ± 12.2 h vs. 19.1 ± 1.42 h) of oxypurinol.,Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33931953/),h,19.1,125513,DB00437,Allopurinol
,6825385,bioavailability,"After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy.","Atenolol interaction with aspirin, allopurinol, and ampicillin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),%,36,126959,DB00437,Allopurinol
,6825385,bioavailability,"After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy.","Atenolol interaction with aspirin, allopurinol, and ampicillin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),%,60,126960,DB00437,Allopurinol
,6825385,bioavailability,During long-term treatment with atenolol and ampicillin the bioavailability of atenolol fell to 24% (P less than 0.01).,"Atenolol interaction with aspirin, allopurinol, and ampicillin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),%,24,126961,DB00437,Allopurinol
,6825385,peak plasma levels,Mean peak plasma levels were lowered from 511 +/- 59 ng/ml on monotherapy to 344 +/- 33 ng/ml after the combination with ampicillin.,"Atenolol interaction with aspirin, allopurinol, and ampicillin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),[ng] / [ml],511,126962,DB00437,Allopurinol
,6825385,peak plasma levels,Mean peak plasma levels were lowered from 511 +/- 59 ng/ml on monotherapy to 344 +/- 33 ng/ml after the combination with ampicillin.,"Atenolol interaction with aspirin, allopurinol, and ampicillin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825385/),[ng] / [ml],344,126963,DB00437,Allopurinol
,19834958,clearance,"Methotrexate clearance was significantly higher (median, 117.1 mL/minute/m(2) vs 91.1 mL/minute/m(2); P = .019) in patients who received urate oxidase.",Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834958/),[min·ml] / [m(2],117.1,132385,DB00437,Allopurinol
,19834958,clearance,"Methotrexate clearance was significantly higher (median, 117.1 mL/minute/m(2) vs 91.1 mL/minute/m(2); P = .019) in patients who received urate oxidase.",Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834958/),[min·ml] / [m(2],91.1,132386,DB00437,Allopurinol
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],33.5,135472,DB00437,Allopurinol
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],17.9,135473,DB00437,Allopurinol
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],32.3,135474,DB00437,Allopurinol
,2029830,plasma clearance,With mexiletine the plasma clearance of theophylline decreased from 33.5 +/- 2.6 (mean +/- SEM) to 17.9 +/- 1.0 ml/kg per hour in the female group (p less than 0.001) and from 32.3 +/- 2.6 to 19.3 +/- 1.3 ml/kg per hour in the male group (p less than 0.001).,Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2029830/),[ml] / [h·kg],19.3,135475,DB00437,Allopurinol
,19000269,C(max),Maternal C(max) values averaged 41.90 microg/mL (allopurinol) and 3.68 microg/mL (oxypurinol).,Placental transfer and pharmacokinetics of allopurinol in late pregnant sows and their fetuses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000269/),[μg] / [ml],41.90,142278,DB00437,Allopurinol
,19000269,C(max),Maternal C(max) values averaged 41.90 microg/mL (allopurinol) and 3.68 microg/mL (oxypurinol).,Placental transfer and pharmacokinetics of allopurinol in late pregnant sows and their fetuses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000269/),[μg] / [ml],3.68,142279,DB00437,Allopurinol
,19000269,C(max),Allopurinol crossed the placental barrier as shown by the average fetal C(max) values of 5.05 microg/mL at 1.47 h after allopurinol administration to the sow.,Placental transfer and pharmacokinetics of allopurinol in late pregnant sows and their fetuses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000269/),[μg] / [ml],5.05,142280,DB00437,Allopurinol
,24227961,flow rate,The elution was isocratic at ambient temperature with a flow rate of 0.75 ml/min.,A new and simple HPLC method for determination of etamsylate in human plasma and its application to pharmacokinetic study in healthy adult male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24227961/),[ml] / [min],0.75,154161,DB00437,Allopurinol
,8824688,half-life,"Cyclophosphamide half-life varied between 1.1 and 16.8 h, clearance varied between 1.2 and 10.61 h-1 m-2 and volume of distribution varied between 0.26 and 1.48 1 kg-1.",Cyclophosphamide pharmacokinetics in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824688/),h,1.1 and 16.8,156673,DB00437,Allopurinol
,8824688,clearance,"Cyclophosphamide half-life varied between 1.1 and 16.8 h, clearance varied between 1.2 and 10.61 h-1 m-2 and volume of distribution varied between 0.26 and 1.48 1 kg-1.",Cyclophosphamide pharmacokinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824688/),1/[(m)^2·h],1.2 and 10.61,156674,DB00437,Allopurinol
,8824688,volume of distribution,"Cyclophosphamide half-life varied between 1.1 and 16.8 h, clearance varied between 1.2 and 10.61 h-1 m-2 and volume of distribution varied between 0.26 and 1.48 1 kg-1.",Cyclophosphamide pharmacokinetics in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824688/),[1] / [kg],0.26 and 1.48,156675,DB00437,Allopurinol
,8824688,clearance,4. Children who had received prior treatment with dexamethasone showed a mean increase in clearance of 2.51 h-1 m-2 (P = 0.001) presumably as a result of CYP450 enzyme induction.,Cyclophosphamide pharmacokinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824688/),1/[(m)^2·h],2.51,156676,DB00437,Allopurinol
,18193917,steady-state plasma oxypurinol concentrations,"Coadministration of allopurinol and probenecid significantly reduced average steady-state plasma oxypurinol concentrations (mean+/-SD: allopurinol alone 9.7+/-2.1 mg/L vs combination 5.1+/-1.0 mg/L, p<0.001).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mg] / [l],9.7,158464,DB00437,Allopurinol
,18193917,steady-state plasma oxypurinol concentrations,"Coadministration of allopurinol and probenecid significantly reduced average steady-state plasma oxypurinol concentrations (mean+/-SD: allopurinol alone 9.7+/-2.1 mg/L vs combination 5.1+/-1.0 mg/L, p<0.001).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mg] / [l],5.1,158465,DB00437,Allopurinol
,18193917,Plasma urate concentrations,"Plasma urate concentrations decreased (p<0.01) during allopurinol therapy (0.16+/-0.05 mmol/L), probenecid therapy (0.13+/-0.02 mmol/L) and combination therapy (0.09+/-0.02 mmol/L) compared with baseline (0.30+/-0.05 mmol/L).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mM] / [l],0.16,158466,DB00437,Allopurinol
,18193917,Plasma urate concentrations,"Plasma urate concentrations decreased (p<0.01) during allopurinol therapy (0.16+/-0.05 mmol/L), probenecid therapy (0.13+/-0.02 mmol/L) and combination therapy (0.09+/-0.02 mmol/L) compared with baseline (0.30+/-0.05 mmol/L).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mM] / [l],0.13,158467,DB00437,Allopurinol
,18193917,Plasma urate concentrations,"Plasma urate concentrations decreased (p<0.01) during allopurinol therapy (0.16+/-0.05 mmol/L), probenecid therapy (0.13+/-0.02 mmol/L) and combination therapy (0.09+/-0.02 mmol/L) compared with baseline (0.30+/-0.05 mmol/L).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mM] / [l],0.09,158468,DB00437,Allopurinol
,18193917,Plasma urate concentrations,"Plasma urate concentrations decreased (p<0.01) during allopurinol therapy (0.16+/-0.05 mmol/L), probenecid therapy (0.13+/-0.02 mmol/L) and combination therapy (0.09+/-0.02 mmol/L) compared with baseline (0.30+/-0.05 mmol/L).",Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193917/),[mM] / [l],0.30,158469,DB00437,Allopurinol
,6407848,plasma half-life,"In 9 with total renal failure, the plasma half-life ranged from 16.6 to 42.7 h and total plasma clearance from 35 to 94 ml/min.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,16.6 to 42.7,170295,DB00437,Allopurinol
,6407848,total plasma clearance,"In 9 with total renal failure, the plasma half-life ranged from 16.6 to 42.7 h and total plasma clearance from 35 to 94 ml/min.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),[ml] / [min],35 to 94,170296,DB00437,Allopurinol
,6407848,half-life,The mean half-life in the remaining patients was 22.3 +/- 4.8 h (+/- SD).,Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,22.3,170297,DB00437,Allopurinol
,6407848,half-life,"During a 4 h haemodialysis, the half-life in the 9 patients decreased to 8.5 +/- 4.6 h, which was calculated to correspond to removal of 25 +/- 14% of the drug from the body.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,8.5,170298,DB00437,Allopurinol
,6407848,half-life,In 6 patients with impaired renal function (creatinine clearance 10-55 ml/min) the tocainide half-life ranged from 13.2 to 22.0 h and total plasma clearance from 72 to 122 ml/min.,Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,13.2 to 22.0,170299,DB00437,Allopurinol
,6407848,total plasma clearance,In 6 patients with impaired renal function (creatinine clearance 10-55 ml/min) the tocainide half-life ranged from 13.2 to 22.0 h and total plasma clearance from 72 to 122 ml/min.,Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),[ml] / [min],72 to 122,170300,DB00437,Allopurinol
,6407848,half-life,"One patient was taking allopurinol and 1 dihydralazine, and the mean half-life in the others was 19.2 +/- 4.0 h.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,19.2,170301,DB00437,Allopurinol
,21385103,absolute bioavailability,"FK3453 showed favourable profiles in preclinical pharmacokinetic studies, including satisfactory absolute bioavailability and total body clearance in animals (30.5%-41.4%, 54.7%-68.2%, and 71.3%-93.4% and 10.8-17.6, 1.9-17.1, and 5.0 mL/min/kg in male rats, female rats, and dogs, respectively), and good metabolic stability in liver microsomes (42.3, 14.5, and 1.1 mL/min/kg in male rats, dogs, and humans, respectively).","Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21385103/),%,30.5,177893,DB00437,Allopurinol
,21385103,total body clearance,"FK3453 showed favourable profiles in preclinical pharmacokinetic studies, including satisfactory absolute bioavailability and total body clearance in animals (30.5%-41.4%, 54.7%-68.2%, and 71.3%-93.4% and 10.8-17.6, 1.9-17.1, and 5.0 mL/min/kg in male rats, female rats, and dogs, respectively), and good metabolic stability in liver microsomes (42.3, 14.5, and 1.1 mL/min/kg in male rats, dogs, and humans, respectively).","Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21385103/),%,71.3,177894,DB00437,Allopurinol
,21385103,total body clearance,"FK3453 showed favourable profiles in preclinical pharmacokinetic studies, including satisfactory absolute bioavailability and total body clearance in animals (30.5%-41.4%, 54.7%-68.2%, and 71.3%-93.4% and 10.8-17.6, 1.9-17.1, and 5.0 mL/min/kg in male rats, female rats, and dogs, respectively), and good metabolic stability in liver microsomes (42.3, 14.5, and 1.1 mL/min/kg in male rats, dogs, and humans, respectively).","Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21385103/),[ml] / [kg·min],10.8-17.6,177895,DB00437,Allopurinol
,21385103,total body clearance,"FK3453 showed favourable profiles in preclinical pharmacokinetic studies, including satisfactory absolute bioavailability and total body clearance in animals (30.5%-41.4%, 54.7%-68.2%, and 71.3%-93.4% and 10.8-17.6, 1.9-17.1, and 5.0 mL/min/kg in male rats, female rats, and dogs, respectively), and good metabolic stability in liver microsomes (42.3, 14.5, and 1.1 mL/min/kg in male rats, dogs, and humans, respectively).","Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21385103/),[ml] / [kg·min],1.9-17.1,177896,DB00437,Allopurinol
,21385103,total body clearance,"FK3453 showed favourable profiles in preclinical pharmacokinetic studies, including satisfactory absolute bioavailability and total body clearance in animals (30.5%-41.4%, 54.7%-68.2%, and 71.3%-93.4% and 10.8-17.6, 1.9-17.1, and 5.0 mL/min/kg in male rats, female rats, and dogs, respectively), and good metabolic stability in liver microsomes (42.3, 14.5, and 1.1 mL/min/kg in male rats, dogs, and humans, respectively).","Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21385103/),[ml] / [kg·min],5.0,177897,DB00437,Allopurinol
,21385103,metabolic stability,"FK3453 showed favourable profiles in preclinical pharmacokinetic studies, including satisfactory absolute bioavailability and total body clearance in animals (30.5%-41.4%, 54.7%-68.2%, and 71.3%-93.4% and 10.8-17.6, 1.9-17.1, and 5.0 mL/min/kg in male rats, female rats, and dogs, respectively), and good metabolic stability in liver microsomes (42.3, 14.5, and 1.1 mL/min/kg in male rats, dogs, and humans, respectively).","Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21385103/),[ml] / [kg·min],42.3,177898,DB00437,Allopurinol
,21385103,metabolic stability,"FK3453 showed favourable profiles in preclinical pharmacokinetic studies, including satisfactory absolute bioavailability and total body clearance in animals (30.5%-41.4%, 54.7%-68.2%, and 71.3%-93.4% and 10.8-17.6, 1.9-17.1, and 5.0 mL/min/kg in male rats, female rats, and dogs, respectively), and good metabolic stability in liver microsomes (42.3, 14.5, and 1.1 mL/min/kg in male rats, dogs, and humans, respectively).","Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21385103/),[ml] / [kg·min],14.5,177899,DB00437,Allopurinol
,21385103,metabolic stability,"FK3453 showed favourable profiles in preclinical pharmacokinetic studies, including satisfactory absolute bioavailability and total body clearance in animals (30.5%-41.4%, 54.7%-68.2%, and 71.3%-93.4% and 10.8-17.6, 1.9-17.1, and 5.0 mL/min/kg in male rats, female rats, and dogs, respectively), and good metabolic stability in liver microsomes (42.3, 14.5, and 1.1 mL/min/kg in male rats, dogs, and humans, respectively).","Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21385103/),[ml] / [kg·min],1.1,177900,DB00437,Allopurinol
,7157458,Vmax,"The Vmax values (mg/kg/day) were 16.1 without allopurinol, and 12.4 and 10.9 with allopurinol (150 and 200 mg/day), respectively, whereas those for Km remained relatively constant (3.9 to 4.9 microgram/ml).",Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157458/),,16.1,182138,DB00437,Allopurinol
,7157458,Vmax,"The Vmax values (mg/kg/day) were 16.1 without allopurinol, and 12.4 and 10.9 with allopurinol (150 and 200 mg/day), respectively, whereas those for Km remained relatively constant (3.9 to 4.9 microgram/ml).",Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157458/),,12.4,182139,DB00437,Allopurinol
,7157458,Vmax,"The Vmax values (mg/kg/day) were 16.1 without allopurinol, and 12.4 and 10.9 with allopurinol (150 and 200 mg/day), respectively, whereas those for Km remained relatively constant (3.9 to 4.9 microgram/ml).",Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157458/),,10.9,182140,DB00437,Allopurinol
,7157458,Km,"The Vmax values (mg/kg/day) were 16.1 without allopurinol, and 12.4 and 10.9 with allopurinol (150 and 200 mg/day), respectively, whereas those for Km remained relatively constant (3.9 to 4.9 microgram/ml).",Phenytoin--allopurinol interaction: Michaelis--Menten kinetic parameters of phenytoin with and without allopurinol in a child with Lesch--Nyhan syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157458/),[μg] / [ml],3.9 to 4.9,182141,DB00437,Allopurinol
,30870504,total chromatographic run time,"The mobile phase consisting of acetonitrile, water and formic acid (95:5:0.1, v/v/v), were eluted at 0.3 mL/min flow rate having total chromatographic run time of 3 min per sample.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),[min] / [sample],3,185738,DB00437,Allopurinol
,30870504,precursor,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,134.94,185739,DB00437,Allopurinol
,30870504,precursor,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,64.07,185740,DB00437,Allopurinol
,30870504,precursor,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,150.89,185741,DB00437,Allopurinol
,30870504,precursor,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,401.90,185742,DB00437,Allopurinol
>,30870504,precursor,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,128.85,185743,DB00437,Allopurinol
,30870504,m/z,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,134.94,185744,DB00437,Allopurinol
,30870504,m/z,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,64.07,185745,DB00437,Allopurinol
,30870504,m/z,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,150.89,185746,DB00437,Allopurinol
>,30870504,m/z,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,41.91,185747,DB00437,Allopurinol
,30870504,m/z,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,401.90,185748,DB00437,Allopurinol
>,30870504,m/z,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,176.79,185749,DB00437,Allopurinol
>,30870504,m/z,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,128.85,185750,DB00437,Allopurinol
>,30870504,m/z,"The precursor to product ion transition of m/z 134.94 > 64.07 for allopurinol, 150.89 > 41.91 for oxypurinol, 401.90 > 176.79 for lesinurad and 128.85 >41.92 for internal standard were used for identification and quantification.","Ultra-performance hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry for simultaneous determination of allopurinol, oxypurinol and lesinurad in rat plasma: Application to pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30870504/),,41.92,185751,DB00437,Allopurinol
≤,25503162,S-UA,All patients achieved S-UA ≤ 7.5 mg/dl.,"Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503162/),[mg] / [dl],7.5,188051,DB00437,Allopurinol
,25503162,concentrations,"Serum febuxostat concentrations at 2 h after administration were 891.8 ± 285.0 ng/ml (mean ± SE) for the 40-mg dose and 770.6 ± 242.7 ng/ml for the 60-mg dose (p=0.80, unpaired t-test), showing no accumulation in patients with renal impairment.","Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503162/),[ng] / [ml],891.8,188052,DB00437,Allopurinol
,25503162,concentrations,"Serum febuxostat concentrations at 2 h after administration were 891.8 ± 285.0 ng/ml (mean ± SE) for the 40-mg dose and 770.6 ± 242.7 ng/ml for the 60-mg dose (p=0.80, unpaired t-test), showing no accumulation in patients with renal impairment.","Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25503162/),[ng] / [ml],770.6,188053,DB00437,Allopurinol
,7094203,clearance,"The following mean (+/- SD) values were obtained from the intravenous allopurinol experiment: clearance, 9.62 +/- 3.49 ml . kg-1 . min-1; Vd, 1.61 +/- 0.74 l/kg; t1/2, 1.62 h.","Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094203/),[ml] / [kg·min],9.62,197192,DB00437,Allopurinol
,7094203,Vd,"The following mean (+/- SD) values were obtained from the intravenous allopurinol experiment: clearance, 9.62 +/- 3.49 ml . kg-1 . min-1; Vd, 1.61 +/- 0.74 l/kg; t1/2, 1.62 h.","Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094203/),[l] / [kg],1.61,197193,DB00437,Allopurinol
,7094203,t1/2,"The following mean (+/- SD) values were obtained from the intravenous allopurinol experiment: clearance, 9.62 +/- 3.49 ml . kg-1 . min-1; Vd, 1.61 +/- 0.74 l/kg; t1/2, 1.62 h.","Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094203/),h,1.62,197194,DB00437,Allopurinol
,7094203,t1/2,Oxipurinol had a mean t1/2 of 16.90 h.,"Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094203/),h,16.90,197195,DB00437,Allopurinol
,7094203,absolute systemic bioavailability,"The absolute systemic bioavailability of the oral tablet was 67% +/- 23%, while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects.","Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094203/),%,67,197196,DB00437,Allopurinol
,1778540,area under the concentration time curve,"The area under the concentration time curve for allopurinol was 40.3 +/- 9.3 mumol l-1 h after AL, against 8.4 +/- 3.9 mumol-1 h after AL + BZB, while for oxypurinol it was 948.0 +/- 125.4 mumol l-1 h after AL and 285.2 +/- 77.9 mumol l-1 h after AL + BZB.",Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778540/),[h·μM] / [l],40.3,200724,DB00437,Allopurinol
,1778540,area under the concentration time curve,"The area under the concentration time curve for allopurinol was 40.3 +/- 9.3 mumol l-1 h after AL, against 8.4 +/- 3.9 mumol-1 h after AL + BZB, while for oxypurinol it was 948.0 +/- 125.4 mumol l-1 h after AL and 285.2 +/- 77.9 mumol l-1 h after AL + BZB.",Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778540/),[h] / [μM],8.4,200725,DB00437,Allopurinol
,1778540,area under the concentration time curve,"The area under the concentration time curve for allopurinol was 40.3 +/- 9.3 mumol l-1 h after AL, against 8.4 +/- 3.9 mumol-1 h after AL + BZB, while for oxypurinol it was 948.0 +/- 125.4 mumol l-1 h after AL and 285.2 +/- 77.9 mumol l-1 h after AL + BZB.",Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778540/),[h·μM] / [l],948.0,200726,DB00437,Allopurinol
,1778540,area under the concentration time curve,"The area under the concentration time curve for allopurinol was 40.3 +/- 9.3 mumol l-1 h after AL, against 8.4 +/- 3.9 mumol-1 h after AL + BZB, while for oxypurinol it was 948.0 +/- 125.4 mumol l-1 h after AL and 285.2 +/- 77.9 mumol l-1 h after AL + BZB.",Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778540/),[h·μM] / [l],285.2,200727,DB00437,Allopurinol
,1778540,Renal clearance,Renal clearance of xanthine was significantly increased under AL + BZB (173.1 +/- 65.6 ml/min against 112.2 +/- 32.9 ml/min after AL).,Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778540/),[ml] / [min],173.1,200728,DB00437,Allopurinol
,1778540,Renal clearance,Renal clearance of xanthine was significantly increased under AL + BZB (173.1 +/- 65.6 ml/min against 112.2 +/- 32.9 ml/min after AL).,Kinetics of allopurinol and its metabolite oxypurinol after oral administration of allopurinol alone or associated with benzbromarone in man. Simultaneous assay of hypoxanthine and xanthine by gas chromatography-mass spectrometry. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778540/),[ml] / [min],112.2,200729,DB00437,Allopurinol
,17655371,oral bioavailability,"The pharmacokinetic parameters of allopurinol after oral dosage include oral bioavailability of 79 +/- 20% (mean +/- SD), an elimination half-life (t((1/2))) of 1.2 +/- 0.3 hours, apparent oral clearance (CL/F) of 15.8 +/- 5.2 mL/min/kg and an apparent volume of distribution after oral administration (V(d)/F) of 1.31 +/- 0.41 L/kg.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),%,79,200787,DB00437,Allopurinol
,17655371,elimination half-life (t((1/2))),"The pharmacokinetic parameters of allopurinol after oral dosage include oral bioavailability of 79 +/- 20% (mean +/- SD), an elimination half-life (t((1/2))) of 1.2 +/- 0.3 hours, apparent oral clearance (CL/F) of 15.8 +/- 5.2 mL/min/kg and an apparent volume of distribution after oral administration (V(d)/F) of 1.31 +/- 0.41 L/kg.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),h,1.2,200788,DB00437,Allopurinol
,17655371,apparent oral clearance (CL/F),"The pharmacokinetic parameters of allopurinol after oral dosage include oral bioavailability of 79 +/- 20% (mean +/- SD), an elimination half-life (t((1/2))) of 1.2 +/- 0.3 hours, apparent oral clearance (CL/F) of 15.8 +/- 5.2 mL/min/kg and an apparent volume of distribution after oral administration (V(d)/F) of 1.31 +/- 0.41 L/kg.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),[ml] / [kg·min],15.8,200789,DB00437,Allopurinol
,17655371,apparent volume of distribution after oral administration (V(d)/F),"The pharmacokinetic parameters of allopurinol after oral dosage include oral bioavailability of 79 +/- 20% (mean +/- SD), an elimination half-life (t((1/2))) of 1.2 +/- 0.3 hours, apparent oral clearance (CL/F) of 15.8 +/- 5.2 mL/min/kg and an apparent volume of distribution after oral administration (V(d)/F) of 1.31 +/- 0.41 L/kg.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),[l] / [kg],1.31,200790,DB00437,Allopurinol
,17655371,t((1/2)),"Assuming that 90 mg of oxypurinol is formed from every 100mg of allopurinol, the pharmacokinetic parameters of oxypurinol in subjects with normal renal function are a t((1/2)) of 23.3 +/- 6.0 hours, CL/F of 0.31 +/- 0.07 mL/min/kg, V(d)/F of 0.59 +/- 0.16 L/kg, and renal clearance (CL(R)) relative to creatinine clearance of 0.19 +/- 0.06.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),h,23.3,200791,DB00437,Allopurinol
,17655371,CL/F,"Assuming that 90 mg of oxypurinol is formed from every 100mg of allopurinol, the pharmacokinetic parameters of oxypurinol in subjects with normal renal function are a t((1/2)) of 23.3 +/- 6.0 hours, CL/F of 0.31 +/- 0.07 mL/min/kg, V(d)/F of 0.59 +/- 0.16 L/kg, and renal clearance (CL(R)) relative to creatinine clearance of 0.19 +/- 0.06.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),[ml] / [kg·min],0.31,200792,DB00437,Allopurinol
,17655371,V(d)/F,"Assuming that 90 mg of oxypurinol is formed from every 100mg of allopurinol, the pharmacokinetic parameters of oxypurinol in subjects with normal renal function are a t((1/2)) of 23.3 +/- 6.0 hours, CL/F of 0.31 +/- 0.07 mL/min/kg, V(d)/F of 0.59 +/- 0.16 L/kg, and renal clearance (CL(R)) relative to creatinine clearance of 0.19 +/- 0.06.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),[l] / [kg],0.59,200793,DB00437,Allopurinol
,17655371,renal clearance (CL(R)),"Assuming that 90 mg of oxypurinol is formed from every 100mg of allopurinol, the pharmacokinetic parameters of oxypurinol in subjects with normal renal function are a t((1/2)) of 23.3 +/- 6.0 hours, CL/F of 0.31 +/- 0.07 mL/min/kg, V(d)/F of 0.59 +/- 0.16 L/kg, and renal clearance (CL(R)) relative to creatinine clearance of 0.19 +/- 0.06.",Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17655371/),,0.19,200794,DB00437,Allopurinol
,2938841,terminal (beta) serum half-life,Pharmacokinetic studies employing high-performance liquid chromatography (HPLC) demonstrated a terminal (beta) serum half-life of 2.19 h.,"Clinical and clinical pharmacologic studies of 2-amino-1,3,4-thiadiazole (A-TDA:NSC 4728). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2938841/),h,2.19,203070,DB00437,Allopurinol
,32126445,flow,"Separation of allopurinol and oxypurinol occurred in a flow of 0.8 mL/min on a C8 reverse phase column 5 μm, and acyclovir was the internal standard.",Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: Focus on veterinary clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32126445/),[ml] / [min],0.8,207796,DB00437,Allopurinol
,7094197,initial half-life (t1/2),"[35S]-beta-TGdR (5.4 mg/kg, 200 mg/m2, 200 microCi total) was administered to five patients; the radiolabel in the plasma declined with an initial half-life (t1/2) of 14 min and a terminal t1/2 of 19.3 h.",Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094197/),min,14,209825,DB00437,Allopurinol
,7094197,terminal t1/2,"[35S]-beta-TGdR (5.4 mg/kg, 200 mg/m2, 200 microCi total) was administered to five patients; the radiolabel in the plasma declined with an initial half-life (t1/2) of 14 min and a terminal t1/2 of 19.3 h.",Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094197/),h,19.3,209826,DB00437,Allopurinol
,7094197,initial t1/2,"In contrast, after administration of [35S]-6-TG (3.4 mg/kg, 125 mg/m2, 200 microCi total) the average initial t1/2 was 40 min while the terminal phase t1/2 was 28.9 h.",Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094197/),min,40,209827,DB00437,Allopurinol
,7094197,terminal phase t1/2,"In contrast, after administration of [35S]-6-TG (3.4 mg/kg, 125 mg/m2, 200 microCi total) the average initial t1/2 was 40 min while the terminal phase t1/2 was 28.9 h.",Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094197/),h,28.9,209828,DB00437,Allopurinol
,7307231,terminal t 1/2,Plasma radioactivity declined biphasically with an average terminal t 1/2 of 3.7 h.,Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307231/),h,3.7,210299,DB00437,Allopurinol
,7307231,terminal plasma t 1/2,"In another four dogs that received 100 mg/kg (2.71 g), the average terminal plasma t 1/2 was 7.7 h and the 5-h cumulative urinary excretion was 28% of the total dose.",Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307231/),h,7.7,210300,DB00437,Allopurinol
,7307231,cumulative urinary excretion,"In another four dogs that received 100 mg/kg (2.71 g), the average terminal plasma t 1/2 was 7.7 h and the 5-h cumulative urinary excretion was 28% of the total dose.",Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307231/),h,5,210301,DB00437,Allopurinol
,7307231,cumulative urinary excretion,"In another four dogs that received 100 mg/kg (2.71 g), the average terminal plasma t 1/2 was 7.7 h and the 5-h cumulative urinary excretion was 28% of the total dose.",Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307231/),%,28,210302,DB00437,Allopurinol
,7307231,terminal t 1/2,"The average terminal t 1/2 of [35S]TG and metabolites was 4.6 h, and the 5-h cumulative urinary excretion of the [35S] label was 47%.",Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307231/),h,4.6,210303,DB00437,Allopurinol
,7307231,cumulative urinary excretion,"The average terminal t 1/2 of [35S]TG and metabolites was 4.6 h, and the 5-h cumulative urinary excretion of the [35S] label was 47%.",Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307231/),%,47,210304,DB00437,Allopurinol
,7307231,terminal phase t 1/2,"In these studies, however, the terminal phase t 1/2 of 14C in plasma was 1.9 h.",Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307231/),h,1.9,210305,DB00437,Allopurinol
,7307231,urinary excretion,Cumulative urinary excretion of the 14C was 40% in 5 h.,Disposition and metabolism of thiopurines III. beta-2'-Deoxythioguanosine and 6-thioguanine in the dog. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307231/),%,40,210306,DB00437,Allopurinol
,3802111,beta-half-time,"Pharmacokinetic analysis revealed tiazofurin plasma elimination to be at least biphasic, with a beta-half-time of 4.2 hours; most of an injected dose could be recovered from the urine as unaltered compound within 24 hours.","Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802111/),h,4.2,215224,DB00437,Allopurinol
,7223751,bioavailability,"The bioavailability of allopurinol from the cocoa butter suppository, relative to the tablet, was 5.77 +/- 2.5%.",Bioavailability of allopurinol oral and rectal dosage forms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7223751/),%,5.77,224259,DB00437,Allopurinol
,4086242,half-life,"HPLC measurement of drug levels demonstrated steady-state plasma levels during the infusion, and a half-life following the infusion of 7.7 +/- 0.6 hours.","Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4086242/),h,7.7,225356,DB00437,Allopurinol
,28438257,AUC<sub>0-tlast<,"The main pharmacokinetic parameters of allopurinol test and reference preparations were as follows: AUC<sub>0-tlast</sub> was 6,725.1 ± 1,390.0 ng×h×mL<sup>-1</sup> and 6,425.6 ± 1,257.6 ng×h×mL<sup>-1</sup>; AUC<sub>0-∞</sub> was 7,069.1 ± 1,503.2 ng×h×mL<sup>-1</sup> and 6,750.6 ± 1,347.7 ng×h×mL<sup>-1</sup>; t<sub>max</sub> was 1.3 ± 0.8 hours and 1.3 ± 0.8 hours; C<sub>max</sub> was 2,203.7 ± 557.4 ng×mL<sup>-1</sup> and 2,310.8 ± 662.8 ng×mL<sup>-1</sup>; and T<sub>1/2</sub> was 2.0 ± 1.6 hours and 1.7 ± 0.7 hours.",Pharmacokinetics and relative bioavailability of two allopurinol tablets in healthy Chinese volunteers . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438257/),[h·ng] / [ml<sup>·sup>],"6,725.1",225434,DB00437,Allopurinol
,28438257,AUC<sub>0-tlast<,"The main pharmacokinetic parameters of allopurinol test and reference preparations were as follows: AUC<sub>0-tlast</sub> was 6,725.1 ± 1,390.0 ng×h×mL<sup>-1</sup> and 6,425.6 ± 1,257.6 ng×h×mL<sup>-1</sup>; AUC<sub>0-∞</sub> was 7,069.1 ± 1,503.2 ng×h×mL<sup>-1</sup> and 6,750.6 ± 1,347.7 ng×h×mL<sup>-1</sup>; t<sub>max</sub> was 1.3 ± 0.8 hours and 1.3 ± 0.8 hours; C<sub>max</sub> was 2,203.7 ± 557.4 ng×mL<sup>-1</sup> and 2,310.8 ± 662.8 ng×mL<sup>-1</sup>; and T<sub>1/2</sub> was 2.0 ± 1.6 hours and 1.7 ± 0.7 hours.",Pharmacokinetics and relative bioavailability of two allopurinol tablets in healthy Chinese volunteers . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438257/),[h·ng] / [ml<sup>·sup>],"6,425.6",225435,DB00437,Allopurinol
,28438257,AUC<sub>0-∞<,"The main pharmacokinetic parameters of allopurinol test and reference preparations were as follows: AUC<sub>0-tlast</sub> was 6,725.1 ± 1,390.0 ng×h×mL<sup>-1</sup> and 6,425.6 ± 1,257.6 ng×h×mL<sup>-1</sup>; AUC<sub>0-∞</sub> was 7,069.1 ± 1,503.2 ng×h×mL<sup>-1</sup> and 6,750.6 ± 1,347.7 ng×h×mL<sup>-1</sup>; t<sub>max</sub> was 1.3 ± 0.8 hours and 1.3 ± 0.8 hours; C<sub>max</sub> was 2,203.7 ± 557.4 ng×mL<sup>-1</sup> and 2,310.8 ± 662.8 ng×mL<sup>-1</sup>; and T<sub>1/2</sub> was 2.0 ± 1.6 hours and 1.7 ± 0.7 hours.",Pharmacokinetics and relative bioavailability of two allopurinol tablets in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438257/),[h·ng] / [ml<sup>·sup>],"7,069.1",225436,DB00437,Allopurinol
,28438257,AUC<sub>0-∞<,"The main pharmacokinetic parameters of allopurinol test and reference preparations were as follows: AUC<sub>0-tlast</sub> was 6,725.1 ± 1,390.0 ng×h×mL<sup>-1</sup> and 6,425.6 ± 1,257.6 ng×h×mL<sup>-1</sup>; AUC<sub>0-∞</sub> was 7,069.1 ± 1,503.2 ng×h×mL<sup>-1</sup> and 6,750.6 ± 1,347.7 ng×h×mL<sup>-1</sup>; t<sub>max</sub> was 1.3 ± 0.8 hours and 1.3 ± 0.8 hours; C<sub>max</sub> was 2,203.7 ± 557.4 ng×mL<sup>-1</sup> and 2,310.8 ± 662.8 ng×mL<sup>-1</sup>; and T<sub>1/2</sub> was 2.0 ± 1.6 hours and 1.7 ± 0.7 hours.",Pharmacokinetics and relative bioavailability of two allopurinol tablets in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438257/),[h·ng] / [ml<sup>·sup>],"6,750.6",225437,DB00437,Allopurinol
,28438257,t<sub>max</sub>,"The main pharmacokinetic parameters of allopurinol test and reference preparations were as follows: AUC<sub>0-tlast</sub> was 6,725.1 ± 1,390.0 ng×h×mL<sup>-1</sup> and 6,425.6 ± 1,257.6 ng×h×mL<sup>-1</sup>; AUC<sub>0-∞</sub> was 7,069.1 ± 1,503.2 ng×h×mL<sup>-1</sup> and 6,750.6 ± 1,347.7 ng×h×mL<sup>-1</sup>; t<sub>max</sub> was 1.3 ± 0.8 hours and 1.3 ± 0.8 hours; C<sub>max</sub> was 2,203.7 ± 557.4 ng×mL<sup>-1</sup> and 2,310.8 ± 662.8 ng×mL<sup>-1</sup>; and T<sub>1/2</sub> was 2.0 ± 1.6 hours and 1.7 ± 0.7 hours.",Pharmacokinetics and relative bioavailability of two allopurinol tablets in healthy Chinese volunteers . ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438257/),h,1.3,225438,DB00437,Allopurinol
,28438257,C<sub>max</sub>,"The main pharmacokinetic parameters of allopurinol test and reference preparations were as follows: AUC<sub>0-tlast</sub> was 6,725.1 ± 1,390.0 ng×h×mL<sup>-1</sup> and 6,425.6 ± 1,257.6 ng×h×mL<sup>-1</sup>; AUC<sub>0-∞</sub> was 7,069.1 ± 1,503.2 ng×h×mL<sup>-1</sup> and 6,750.6 ± 1,347.7 ng×h×mL<sup>-1</sup>; t<sub>max</sub> was 1.3 ± 0.8 hours and 1.3 ± 0.8 hours; C<sub>max</sub> was 2,203.7 ± 557.4 ng×mL<sup>-1</sup> and 2,310.8 ± 662.8 ng×mL<sup>-1</sup>; and T<sub>1/2</sub> was 2.0 ± 1.6 hours and 1.7 ± 0.7 hours.",Pharmacokinetics and relative bioavailability of two allopurinol tablets in healthy Chinese volunteers . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438257/),[ng] / [ml<sup>·sup>],"2,203.7",225439,DB00437,Allopurinol
,28438257,C<sub>max</sub>,"The main pharmacokinetic parameters of allopurinol test and reference preparations were as follows: AUC<sub>0-tlast</sub> was 6,725.1 ± 1,390.0 ng×h×mL<sup>-1</sup> and 6,425.6 ± 1,257.6 ng×h×mL<sup>-1</sup>; AUC<sub>0-∞</sub> was 7,069.1 ± 1,503.2 ng×h×mL<sup>-1</sup> and 6,750.6 ± 1,347.7 ng×h×mL<sup>-1</sup>; t<sub>max</sub> was 1.3 ± 0.8 hours and 1.3 ± 0.8 hours; C<sub>max</sub> was 2,203.7 ± 557.4 ng×mL<sup>-1</sup> and 2,310.8 ± 662.8 ng×mL<sup>-1</sup>; and T<sub>1/2</sub> was 2.0 ± 1.6 hours and 1.7 ± 0.7 hours.",Pharmacokinetics and relative bioavailability of two allopurinol tablets in healthy Chinese volunteers . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438257/),ml<sup>·ng,"2,310.8",225440,DB00437,Allopurinol
,28438257,relative bioavailability,The relative bioavailability was 105.1 ± 12.6%.,Pharmacokinetics and relative bioavailability of two allopurinol tablets in healthy Chinese volunteers . ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438257/),%,105.1,225441,DB00437,Allopurinol
,7711419,Cmax,"For oxipurinol, mean Cmax was not altered on hydrochlorothiazide treatment (13.8 +/- 1.4 micrograms/ml and 14.7 +/- 2.6 micrograms/ml, respectively); mean AUC0-24 was 259 and 290 micrograms h-1 ml-1, respectively.","Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711419/),[μg] / [ml],13.8,229257,DB00437,Allopurinol
,7711419,Cmax,"For oxipurinol, mean Cmax was not altered on hydrochlorothiazide treatment (13.8 +/- 1.4 micrograms/ml and 14.7 +/- 2.6 micrograms/ml, respectively); mean AUC0-24 was 259 and 290 micrograms h-1 ml-1, respectively.","Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711419/),[μg] / [ml],14.7,229258,DB00437,Allopurinol
,7711419,AUC0-24,"For oxipurinol, mean Cmax was not altered on hydrochlorothiazide treatment (13.8 +/- 1.4 micrograms/ml and 14.7 +/- 2.6 micrograms/ml, respectively); mean AUC0-24 was 259 and 290 micrograms h-1 ml-1, respectively.","Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711419/),[μg] / [h·ml],259,229259,DB00437,Allopurinol
,7711419,AUC0-24,"For oxipurinol, mean Cmax was not altered on hydrochlorothiazide treatment (13.8 +/- 1.4 micrograms/ml and 14.7 +/- 2.6 micrograms/ml, respectively); mean AUC0-24 was 259 and 290 micrograms h-1 ml-1, respectively.","Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711419/),[μg] / [h·ml],290,229260,DB00437,Allopurinol
,4038917,plasma steady-state MP concentration,The mean plasma steady-state MP concentration achieved was 6.9 microM with little interpatient variability seen.,Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4038917/),μM,6.9,229628,DB00437,Allopurinol
,4038917,steady-state cerebrospinal fluid:plasma ratio,"The steady-state cerebrospinal fluid:plasma ratio for MP was 0.27, suggesting that this approach may be of value in the treatment of central nervous system cancer.",Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4038917/),,0.27,229629,DB00437,Allopurinol
,10190763,AUC(0-72),While the mean AUC(0-72) values of allopurinol and oxypurinol after the test and reference preparations are entirely identical (5.33 vs.,Bioequivalence of allopurinol-containing tablet preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190763/),,5.33,230899,DB00437,Allopurinol
,10190763,C(max),"137.96 microg h ml(-1), respectively), the C(max) values of oxypurinol unlike those of allopurinol show small differences (4.59 vs. 4.78 and 1.91 vs. 193 microg/ml, respectively).",Bioequivalence of allopurinol-containing tablet preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190763/),[μg] / [ml],4.59,230900,DB00437,Allopurinol
,10190763,C(max),"137.96 microg h ml(-1), respectively), the C(max) values of oxypurinol unlike those of allopurinol show small differences (4.59 vs. 4.78 and 1.91 vs. 193 microg/ml, respectively).",Bioequivalence of allopurinol-containing tablet preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190763/),[μg] / [ml],4.78,230901,DB00437,Allopurinol
,10190763,C(max),"137.96 microg h ml(-1), respectively), the C(max) values of oxypurinol unlike those of allopurinol show small differences (4.59 vs. 4.78 and 1.91 vs. 193 microg/ml, respectively).",Bioequivalence of allopurinol-containing tablet preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190763/),[μg] / [ml],1.91,230902,DB00437,Allopurinol
,10190763,C(max),"137.96 microg h ml(-1), respectively), the C(max) values of oxypurinol unlike those of allopurinol show small differences (4.59 vs. 4.78 and 1.91 vs. 193 microg/ml, respectively).",Bioequivalence of allopurinol-containing tablet preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10190763/),[μg] / [ml],193,230903,DB00437,Allopurinol
,16778717,volume of the central compartment (V,"Estimated pharmacokinetic parameters were volume of the central compartment (V, 0.79 L/kg) and total body clearance (CL, 0.078 L/h/kg), with 42% and 60% interindividual variability, respectively.",Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778717/),[l] / [kg],0.79,242427,DB00437,Allopurinol
,16778717,total body clearance (CL,"Estimated pharmacokinetic parameters were volume of the central compartment (V, 0.79 L/kg) and total body clearance (CL, 0.078 L/h/kg), with 42% and 60% interindividual variability, respectively.",Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778717/),[l] / [h·kg],0.078,242428,DB00437,Allopurinol
,9131540,elimination constant (Kel),"In the i.v. kinetic study, the elimination constant (Kel) = 0.31 +/- 0.03 per h, the half-life (t1/2) = 2.22 +/- 0.20 h, the initial concentration (C0) = 5.26 +/- 0.34 micrograms/mL and the specific volume (Vd) = 1.14 +/- 0.07 L/kg.",Pharmacokinetics of allopurinol in Dalmatian dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),1/[h],0.31,246261,DB00437,Allopurinol
,9131540,half-life (t1/2),"In the i.v. kinetic study, the elimination constant (Kel) = 0.31 +/- 0.03 per h, the half-life (t1/2) = 2.22 +/- 0.20 h, the initial concentration (C0) = 5.26 +/- 0.34 micrograms/mL and the specific volume (Vd) = 1.14 +/- 0.07 L/kg.",Pharmacokinetics of allopurinol in Dalmatian dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),h,2.22,246262,DB00437,Allopurinol
,9131540,initial concentration (C0),"In the i.v. kinetic study, the elimination constant (Kel) = 0.31 +/- 0.03 per h, the half-life (t1/2) = 2.22 +/- 0.20 h, the initial concentration (C0) = 5.26 +/- 0.34 micrograms/mL and the specific volume (Vd) = 1.14 +/- 0.07 L/kg.",Pharmacokinetics of allopurinol in Dalmatian dogs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),[μg] / [ml],5.26,246263,DB00437,Allopurinol
,9131540,specific volume (Vd),"In the i.v. kinetic study, the elimination constant (Kel) = 0.31 +/- 0.03 per h, the half-life (t1/2) = 2.22 +/- 0.20 h, the initial concentration (C0) = 5.26 +/- 0.34 micrograms/mL and the specific volume (Vd) = 1.14 +/- 0.07 L/kg.",Pharmacokinetics of allopurinol in Dalmatian dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),[l] / [kg],1.14,246264,DB00437,Allopurinol
,9131540,Clearance,Clearance of allopurinol was estimated to be 0.36 +/- 0.03 L/kg.h.,Pharmacokinetics of allopurinol in Dalmatian dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),[l] / [h·kg],0.36,246265,DB00437,Allopurinol
,9131540,absorption rate constant (Kab),"In the oral kinetic study, the absorption rate constant (Kab) = 1.06 +/- 0.13 per h, the elimination rate constant (Kel) = 0.26 +/- 0.01 per h, the absorption half-life (t1/2ab) = 0.66 +/- 0.06 h, and the elimination half-life (t1/2el) = 2.69 +/- 0.14 h.",Pharmacokinetics of allopurinol in Dalmatian dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),1/[h],1.06,246266,DB00437,Allopurinol
,9131540,elimination rate constant (Kel),"In the oral kinetic study, the absorption rate constant (Kab) = 1.06 +/- 0.13 per h, the elimination rate constant (Kel) = 0.26 +/- 0.01 per h, the absorption half-life (t1/2ab) = 0.66 +/- 0.06 h, and the elimination half-life (t1/2el) = 2.69 +/- 0.14 h.",Pharmacokinetics of allopurinol in Dalmatian dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),1/[h],0.26,246267,DB00437,Allopurinol
,9131540,absorption half-life (t1/2ab),"In the oral kinetic study, the absorption rate constant (Kab) = 1.06 +/- 0.13 per h, the elimination rate constant (Kel) = 0.26 +/- 0.01 per h, the absorption half-life (t1/2ab) = 0.66 +/- 0.06 h, and the elimination half-life (t1/2el) = 2.69 +/- 0.14 h.",Pharmacokinetics of allopurinol in Dalmatian dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),h,0.66,246268,DB00437,Allopurinol
,9131540,elimination half-life (t1/2el),"In the oral kinetic study, the absorption rate constant (Kab) = 1.06 +/- 0.13 per h, the elimination rate constant (Kel) = 0.26 +/- 0.01 per h, the absorption half-life (t1/2ab) = 0.66 +/- 0.06 h, and the elimination half-life (t1/2el) = 2.69 +/- 0.14 h.",Pharmacokinetics of allopurinol in Dalmatian dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),h,2.69,246269,DB00437,Allopurinol
,9131540,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) = 6.43 +/- 0.18 micrograms/mL were obtained within 1 to 3 h (mean time of maximum concentration (Tmax) = 1.9 +/- 0.1 h).,Pharmacokinetics of allopurinol in Dalmatian dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),[μg] / [ml],6.43,246270,DB00437,Allopurinol
,9131540,time of maximum concentration (Tmax),Peak plasma concentrations (Cmax) = 6.43 +/- 0.18 micrograms/mL were obtained within 1 to 3 h (mean time of maximum concentration (Tmax) = 1.9 +/- 0.1 h).,Pharmacokinetics of allopurinol in Dalmatian dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),h,1.9,246271,DB00437,Allopurinol
,9131540,volume of distribution corrected by the fraction of dose absorbed (Vd/F),The volume of distribution corrected by the fraction of dose absorbed (Vd/F) was estimated to be 1.17 +/- 0.07 L/kg.,Pharmacokinetics of allopurinol in Dalmatian dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131540/),[l] / [kg],1.17,246272,DB00437,Allopurinol
,7199345,plasma elimination half-life,"After a single p.o. dose of 300 mg allopurinol plasma elimination half-life of the major metabolite oxipurinol was found to be about 40 h with both preparations, calculated from the course of the plasma levels.",[Pharmacokinetic studies on plasma elimination half-life of oxipurinol (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7199345/),h,40,259311,DB00437,Allopurinol
,4033706,half-life,"For oxypurinol, the area under the curve increased nearly three-fold (P less than 0.02), the renal clearance decreased by 64 per cent (P less than 0.02), the fractional excretion decreased by 49 per cent (P less than 0.02), and the plasma oxypurinol half-life increased nearly threefold from 17.3 +/- 1.5 (mean +/- S.E.M.) to 49.9 +/- 2.9 hours (P less than 0.02) during the low-protein diet, as compared with the high-protein diet.",The effect of dietary protein on the clearance of allopurinol and oxypurinol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4033706/),h,17.3,260932,DB00437,Allopurinol
,4033706,half-life,"For oxypurinol, the area under the curve increased nearly three-fold (P less than 0.02), the renal clearance decreased by 64 per cent (P less than 0.02), the fractional excretion decreased by 49 per cent (P less than 0.02), and the plasma oxypurinol half-life increased nearly threefold from 17.3 +/- 1.5 (mean +/- S.E.M.) to 49.9 +/- 2.9 hours (P less than 0.02) during the low-protein diet, as compared with the high-protein diet.",The effect of dietary protein on the clearance of allopurinol and oxypurinol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4033706/),h,49.9,260933,DB00437,Allopurinol
,8145233,t1/2,"No degradation was observed in pH 2 and serum, while in liver homogenate 2'-F-ara-ddP was almost completely converted to 2'-F-ara-ddI within 20 min (t1/2 = 3.54 min).",Enhanced brain delivery of an anti-HIV nucleoside 2'-F-ara-ddI by xanthine oxidase mediated biotransformation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8145233/),min,3.54,265459,DB00437,Allopurinol
,8145233,half-lives,"In order to determine the role of xanthine oxidase in the conversion of 2'-F-ara-ddP to 2'-F-ara-ddI, in vitro studies were conducted in phosphate buffer (pH 7.4) in the presence or absence of allopurinol, in which the half-lives of 2'-F-ara-ddP were 7.4 and 3.4 h, respectively, indicating the conversions were catalyzed by the xanthine oxidase.",Enhanced brain delivery of an anti-HIV nucleoside 2'-F-ara-ddI by xanthine oxidase mediated biotransformation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8145233/),h,7.4,265460,DB00437,Allopurinol
,8145233,half-lives,"In order to determine the role of xanthine oxidase in the conversion of 2'-F-ara-ddP to 2'-F-ara-ddI, in vitro studies were conducted in phosphate buffer (pH 7.4) in the presence or absence of allopurinol, in which the half-lives of 2'-F-ara-ddP were 7.4 and 3.4 h, respectively, indicating the conversions were catalyzed by the xanthine oxidase.",Enhanced brain delivery of an anti-HIV nucleoside 2'-F-ara-ddI by xanthine oxidase mediated biotransformation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8145233/),h,3.4,265461,DB00437,Allopurinol
,8145233,maximum serum concentrations,"The maximum serum concentrations of 2'-F-ara-ddI administered itself and as 2'-F-ara-ddP reached 48.1 +/- 10.00 and 89.3 +/- 26.0 microM and were observed in 1 and 0.25 h, respectively.",Enhanced brain delivery of an anti-HIV nucleoside 2'-F-ara-ddI by xanthine oxidase mediated biotransformation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8145233/),μM,48.1,265462,DB00437,Allopurinol
,8145233,maximum serum concentrations,"The maximum serum concentrations of 2'-F-ara-ddI administered itself and as 2'-F-ara-ddP reached 48.1 +/- 10.00 and 89.3 +/- 26.0 microM and were observed in 1 and 0.25 h, respectively.",Enhanced brain delivery of an anti-HIV nucleoside 2'-F-ara-ddI by xanthine oxidase mediated biotransformation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8145233/),μM,89.3,265463,DB00437,Allopurinol
,8145233,bioavailability,The bioavailability of the prodrug after oral administration was 60.7%.,Enhanced brain delivery of an anti-HIV nucleoside 2'-F-ara-ddI by xanthine oxidase mediated biotransformation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8145233/),%,60.7,265464,DB00437,Allopurinol
,7957522,urinary recovery,"Similarly, mean urinary recovery and renal clearance values of penciclovir following famciclovir alone were 56.8% and 27 l.h-1, and when given with allopurinol 59.7% and 27.5 l.h-1, respectively.",Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957522/),%,56.8,272757,DB00437,Allopurinol
,7957522,urinary recovery,"Similarly, mean urinary recovery and renal clearance values of penciclovir following famciclovir alone were 56.8% and 27 l.h-1, and when given with allopurinol 59.7% and 27.5 l.h-1, respectively.",Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957522/),%,59.7,272758,DB00437,Allopurinol
,7957522,renal clearance,"Similarly, mean urinary recovery and renal clearance values of penciclovir following famciclovir alone were 56.8% and 27 l.h-1, and when given with allopurinol 59.7% and 27.5 l.h-1, respectively.",Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957522/),[l] / [h],27,272759,DB00437,Allopurinol
,7957522,renal clearance,"Similarly, mean urinary recovery and renal clearance values of penciclovir following famciclovir alone were 56.8% and 27 l.h-1, and when given with allopurinol 59.7% and 27.5 l.h-1, respectively.",Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957522/),[l] / [h],27.5,272760,DB00437,Allopurinol
,7957522,Cmax,"Mean Cmax and AUC values of the active metabolite of allopurinol, oxypurinol were 11.2 micrograms.",Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957522/),μg,11.2,272761,DB00437,Allopurinol
